|Bid||1.30 x 1100|
|Ask||1.36 x 300|
|Day's Range||1.31 - 1.39|
|52 Week Range||1.13 - 6.79|
|PE Ratio (TTM)||-1.23|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Q4 2016 Merrimack Pharmaceuticals Inc Earnings Call
Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.